Amgen’s Immuno-Oncology Strategy Hinges On T-VEC’s Mechanism, Combinability
This article was originally published in The Pink Sheet Daily
Executive Summary
Awaiting FDA approval for monotherapy in metastatic melanoma, Amgen uses ASCO to launch new combination studies with Merck and Roche immune checkpoint inhibitors, adding to one ongoing with Bristol’s Yervoy.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.